Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.60 |
| ▸ | BRD4 | O60885 | 6/20 | 0.58 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30045163 | 0.97 | CRBN (0.59) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL19764202 | 0.97 | CRBN (0.59) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL28808722 | 0.96 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL29505442 | 0.96 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL30045339 | 0.96 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL19764203 | 0.96 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL28808737 | 0.96 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL2382398 | 0.96 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL19764204 | 0.96 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL27944615 | 0.96 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433257-A | Imidazopyridazine bifunctional PROTAC molecular compound and preparation and application thereof | 广西大学 | 2022-12-06 | — | — | CN | disclosed |
| CN-114341128-A | Bifunctional protein degradation targeting chimera compound and preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20120071632-A1 | Lenalidomide and Thalidomide Immunoassays | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2012-03-22 | — | — | US | disclosed |
| US-8012997-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012997-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-7576104-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576104-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071632-A1 | Lenalidomide and Thalidomide Immunoassays | FCGRT, MALT1, SERPINA6 | CRBN 26/4885BRD4 504/4885IKZF1 388/4885 |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | TNF, IKZF3, TNFRSF1A | CRBN 1695/4885BRD4 2140/4885IKZF1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.